Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...
Results have been announced from a Phase III trial of Merck & Co’s (NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s (TYO: 4523) orally available multiple ...
The combination of Merck’s Keytruda and Eisai’s Lenvima failed to prolong patients’ lives versus the comparator in another cancer study, but the companies ...
Merck (NYSE:MRK) and Esai (OTCPK:ESALF) (OTCPK:ESAIY) announced Friday a mixed outcome in their Phase 3 LEAP-015 trial, which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Ja ...
Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...
Merck’s mega blockbuster Keytruda paired with Eisai’s Lenvima did not improve overall survival in a Phase III clinical trial of patients with an advanced form of gastroesophageal adenocarcinoma. While ...
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback